Ripretinib (Qinlock®) – Gastrointestinal stromal tumours (GIST), ≥ 3 prior therapies

Characteristics

Start date 01.01.2022
Resolution 16.06.2022
INN Ripretinib
Brand name Qinlock®
Pharm. company Deciphera Pharmaceuticals (Netherlands) B.V.
G-BA procedure ID 2022-01-01-D-782
Therapeutic area Oncological diseases ORPHAN
Reason for procedure Initial assessment

Indication (German)

QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Subpopulation Indication Comparator
Adults with advanced gastrointestinal stromal tumours (GIST) who have previously received treatment with three or more kinase inhibitors, including imatinib. – (Orphan drug)

9. Associated procedures



<< List of all resolutions